U.S. FDA Set To Strengthen Inspections Of Chinese Drugmakers, Search For Adulterants In Aftermath Of Heparin Deaths – CDER Official
This article was originally published in PharmAsia News
Executive Summary
BEIJING - As U.S. FDA leaders select inspectors to deploy across three new offices being set up in China, the organization is also preparing to ramp up the number of inspections and the level of scrutiny of Chinese drugmakers that export to the U.S
You may also be interested in...
US FDA's China Staff Increase Takes Hold As Gottlieb Boosts Border Security
After receiving delayed visas, additional FDA is inspectors and other staff can relocate to China office; Gottlieb also announces increase in international mail facility staff.
FDA Posts OCI Agent In Singapore, But Other Foreign Offices Close
China offices consolidate to allow FDA to 'strategically focus its resources.'
FDA Talks Drug Safety With China, But Visas Still Elusive For Staff
The agency is unable to place more inspectors in China even as Howard Sklamberg, deputy commissioner for global regulatory operations and policy, visits Beijing.